Supplementary Figure S4 from PRMT5 Inhibition by SCR-6920 Downregulates HIF-1α and Exhibits Synergistic Antitumor Activity with Bevacizumab in Ovarian Cancer

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Supplementary Figure S4 shows that high PRMT5 expression correlates with poor overall survival in cancer patients, and demonstrates that SCR-6920 enhances protein ubiquitination under hypoxia while synergizing with chemotherapies (docetaxel, paclitaxel + Avastin) to suppress tumor growth without affecting body weight in xenograft models.